Updated Overall Survival Data from a Phase 3 Trial of Ipilimumab vs. Placebo in Men Post Chemotherapy Receiving Radiation Therapy – Still Needs Time
Presented in a poster at the recent European Society of Medical Oncologist (ESMO) there was a data update of the phase 3 clinical trial (CA184-043) which evaluated overall survival (OS) in men having radiotherapy (RT) followed by either the immunologic drug Ipilimumab (Ipi) or with a placebo. Initially, this trial did not meet its endpoint [...]